Drug Profile

F 14512

Alternative Names: 14512; F14512

Latest Information Update: 13 Mar 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pierre Fabre
Class Acetamides; Antineoplastics; Heterocyclic compounds with 4 or more rings
Mechanism of Action Apoprotein stimulants; Type II DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Mar 2019 Discontinued - Phase-I/II for Acute myeloid leukaemia (Combination therapy, In the elderly, In adults) in Italy, France, Spain (IV)
13 Mar 2019 No development reported - Phase-I/II for Acute myeloid leukaemia (Combination therapy, In the elderly, In adults) in Spain (IV)
15 Feb 2018 Pierre Fabre discontinued a phase-I/II clinical trial in Acute myeloid leukaemia (Combination therapy, In the elderly) in Spain and France (IV) (EudraCT2012-005241-20)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com